Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total value of $199,975.88. Following the transaction, the insider owned 4,332,917 shares in the company, valued at approximately $32,670,194.18. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Bioventures 2014 L.P. Mpm also recently made the following trade(s):
- On Wednesday, August 26th, Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $102,857.14.
- On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.34, for a total value of $158,712.82.
Entrada Therapeutics Price Performance
Entrada Therapeutics stock traded down $0.62 during trading on Wednesday, reaching $7.00. 229,319 shares of the company were exchanged, compared to its average volume of 334,500. Entrada Therapeutics, Inc. has a 52-week low of $5.02 and a 52-week high of $16.45. The company has a market capitalization of $272.58 million, a P/E ratio of -1.77 and a beta of -0.26. The stock’s 50 day simple moving average is $7.08 and its two-hundred day simple moving average is $9.36.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on the stock. Guggenheim dropped their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Finally, Roth Capital reissued a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.75.
View Our Latest Research Report on Entrada Therapeutics
Institutional Investors Weigh In On Entrada Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRDA. State of Wyoming purchased a new position in shares of Entrada Therapeutics during the 2nd quarter worth $37,000. Russell Investments Group Ltd. raised its holdings in Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after buying an additional 3,707 shares during the period. Occudo Quantitative Strategies LP purchased a new stake in Entrada Therapeutics in the 2nd quarter valued at about $68,000. Jain Global LLC acquired a new position in Entrada Therapeutics in the third quarter valued at about $69,000. Finally, IHT Wealth Management LLC acquired a new position in Entrada Therapeutics in the second quarter valued at about $72,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.
Entrada Therapeutics Company Profile
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Featured Articles
- Five stocks we like better than Entrada Therapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
